These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24246704)

  • 21. Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.
    Hesketh PJ; Chansky K; Wozniak AJ; Hirsch FR; Spreafico A; Moon J; Mack PC; Marchello BT; Franklin WA; Crowley JJ; Gandara DR
    J Thorac Oncol; 2008 Sep; 3(9):1026-31. PubMed ID: 18758306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
    Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
    Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Pan G; Ke S; Zhao J
    Target Oncol; 2013 Jun; 8(2):107-16. PubMed ID: 23516098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients.
    Yamazaki N; Kiyohara Y; Kudoh S; Seki A; Fukuoka M
    Int J Clin Oncol; 2016 Apr; 21(2):248-253. PubMed ID: 26499382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
    Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
    J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.
    Davies AM; Ho C; Beckett L; Lau D; Scudder SA; Lara PN; Perkins N; Gandara DR
    J Thorac Oncol; 2009 Jul; 4(7):862-8. PubMed ID: 19494788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.
    Melosky B; Anderson H; Burkes RL; Chu Q; Hao D; Ho V; Ho C; Lam W; Lee CW; Leighl NB; Murray N; Sun S; Winston R; Laskin JJ
    J Clin Oncol; 2016 Mar; 34(8):810-5. PubMed ID: 26573073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
    Groen HJ; Socinski MA; Grossi F; Juhasz E; Gridelli C; Baas P; Butts CA; Chmielowska E; Usari T; Selaru P; Harmon C; Williams JA; Gao F; Tye L; Chao RC; Blumenschein GR
    Ann Oncol; 2013 Sep; 24(9):2382-9. PubMed ID: 23788751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.
    Mazzoni F; Rotella V; Pratesi N; Boni L; Simi L; Orlando C; Comin CE; Maddau C; Di Costanzo F
    Tumori; 2011; 97(2):160-5. PubMed ID: 21617709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
    Natale RB; Thongprasert S; Greco FA; Thomas M; Tsai CM; Sunpaweravong P; Ferry D; Mulatero C; Whorf R; Thompson J; Barlesi F; Langmuir P; Gogov S; Rowbottom JA; Goss GD
    J Clin Oncol; 2011 Mar; 29(8):1059-66. PubMed ID: 21282542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
    Smith DA; Conkling P; Richards DA; Nemunaitis JJ; Boyd TE; Mita AC; de La Bourdonnaye G; Wages D; Bexon AS
    Cancer Immunol Immunother; 2014 Aug; 63(8):787-96. PubMed ID: 24770667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.
    Krzakowski M; Bennouna J; Dansin E; Kowalski D; Hiret S; Penel N; Favrel S; Tourani JM
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):231-6. PubMed ID: 24220936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
    Zhou S; Ren S; Yan L; Zhang L; Tang L; Zhang J; Zhou C
    Respirology; 2009 Jul; 14(5):709-15. PubMed ID: 19659649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
    Ramalingam SS; Blackhall F; Krzakowski M; Barrios CH; Park K; Bover I; Seog Heo D; Rosell R; Talbot DC; Frank R; Letrent SP; Ruiz-Garcia A; Taylor I; Liang JQ; Campbell AK; O'Connell J; Boyer M
    J Clin Oncol; 2012 Sep; 30(27):3337-44. PubMed ID: 22753918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
    Wu YL; Lee JS; Thongprasert S; Yu CJ; Zhang L; Ladrera G; Srimuninnimit V; Sriuranpong V; Sandoval-Tan J; Zhu Y; Liao M; Zhou C; Pan H; Lee V; Chen YM; Sun Y; Margono B; Fuerte F; Chang GC; Seetalarom K; Wang J; Cheng A; Syahruddin E; Qian X; Ho J; Kurnianda J; Liu HE; Jin K; Truman M; Bara I; Mok T
    Lancet Oncol; 2013 Jul; 14(8):777-86. PubMed ID: 23782814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
    Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
    Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
    Gatzemeier U; Pluzanska A; Szczesna A; Kaukel E; Roubec J; De Rosa F; Milanowski J; Karnicka-Mlodkowski H; Pesek M; Serwatowski P; Ramlau R; Janaskova T; Vansteenkiste J; Strausz J; Manikhas GM; Von Pawel J
    J Clin Oncol; 2007 Apr; 25(12):1545-52. PubMed ID: 17442998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
    Choong NW; Mauer AM; Haraf DJ; Lester E; Hoffman PC; Kozloff M; Lin S; Dancey JE; Szeto L; Grushko T; Olopade OI; Salgia R; Vokes EE
    J Thorac Oncol; 2008 Sep; 3(9):1003-11. PubMed ID: 18758303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.